Johnson & Johnson Plans Move Into Vaccines With Bid For Remainder Of Crucell
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal could position the pharma giant to eventually become a sixth major player in the worldwide vaccine space.
You may also be interested in...
Janssen R&D Unveils Three New Research Platforms
With an emphasis on early disease intervention, J&J’s Janssen R&D unit launched three new research platforms – disease prevention, disease interception and the microbiome.
Merck Serono, J&J Step Up Investment For Local Chinese Market With Manufacturing Sites
Despite ongoing compliance probes, decelerating growth and continuing price pressure, Merck KGAA and Johnson & Johnson unveil bold localization plans in China with a fresh investment worth millions. They see the need to support essential drug supply, introduce new products and accelerate product registration in China.
Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals
Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.